ArticleTranslational pediatrics2026
Ibuprofen for hemodynamically significant patent ductus arteriosus in extremely preterm infants: a target trial emulation.
Article in Translational pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The optimal management of patent ductus arteriosus (PDA), particularly hemodynamically significant PDA (hsPDA), in extremely preterm infants remains highly controversial. This study aimed to evaluate whether early ibuprofen for hsPDA was associated with clinically meaningful outcomes in extremely preterm infants and whether this association was modified by clinical tolerance to PDA-related hemodynamic changes. Methods: This prospective cohort study used data from the Chinese Multicenter Collaboration Platform for PDA in Extremely Preterm Infants and included infants with a gestational age ≤29+6 weeks who were admitted between November 2024 and September 2025 and diagnosed with hsPDA by echocardiography on postnatal days 3-5. A target trial emulation framework was applied, with the day of echocardiography as time zero and a 2-day grace period. Ibuprofen initiation within the grace period defined treatment. Inverse probability of treatment weighting was used to balance baseline characteristics and emulate random treatment assignment. Infants were stratified as clinically tolerant and intolerant based on respiratory and hemodynamic support at the time of echocardiography. Outcomes included mortality and major prematurity-related morbidities. Results: A total of 239 infants were included, of whom 65 received ibuprofen within the grace period and 174 did not. In the overall cohort, ibuprofen was associated with a lower, but not statistically significant, risk of mortality [risk ratio (RR), 0.51; 95% confidence interval (CI): 0.25-1.02]. In analyses stratified by clinical tolerance, ibuprofen was associated with a reduced risk of mortality only in the intolerant subgroup (RR, 0.18; 95% CI: 0.06-0.51), but not in the tolerant subgroup (RR, 0.96; 95% CI: 0.23-4.00). Conclusions: The effect of ibuprofen for hsPDA in extremely preterm infants appears heterogeneous, with differences in mortality associations observed across clinical tolerance subgroups. These findings are exploratory and warrant confirmation in future adequately powered randomized trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.